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A B S T R A C T
Background
This is an updated version of the original Cochrane review, published in 2009, Issue 2.
Kleine-Levin syndrome (KLS) is a rare disorder that mainly affects adolescent men. It is characterised by recurrent episodes of hyper-
somnia, usually accompanied by hyperphagia, cognitive and mood disturbances, abnormal behaviour, such as hypersexuality, and signs
of dysautonomia.
In 1990, the diagnostic criteria for Kleine-Levin syndrome were modified in the International Classification of Sleep Disorders, where
KLS was defined as a syndrome comprised of recurring episodes of undue sleepiness lasting some days, which may or may not be
associated with hyperphagia and abnormal behaviour. According to the International Classification of Sleepiness Disorders, 3rd version
(ICSD-3), revised in 2014, the Kleine-Levin syndrome is a disorder characterized by recurrent episodes of hypersomnia that last from
two days to four weeks, with at least annual recurrence, and hyperphagia (rapid consumption of a large amount of food), usually
with onset in early adolescence in males but occasionally in later life and in women. A monosymptomatic form of the disorder with
hypersomnia only can occur without binge eating or hypersexuality.
The cause of Kleine-Levin syndrome remains unknown, and several treatment strategies have been used. Some medications have been
reported to provide benefit in the treatment of patients with KLS, but because of the rarity of the condition, no long-term follow-up
therapies have yet been described.
Objectives
This review aimed to evaluate:
1. whether pharmacological treatment for Kleine Levin syndrome was effective and safe.
2. which drug or category of drugs was effective and safe.
Search methods
For the latest update, we searched the following sources: theCochrane EpilepsyGroup Specialized Register (7 April 2016); theCochrane
Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online CRSO (7 April 2016); MEDLINE
(1946 to April 2016); LILACS (7 April 2016); ClinicalTrials.gov (7 April 2016); WHO International Clinical Trials Registry Platform
ICTRP (7 April 2016); reference lists of sleep medicine textbooks; review articles and reference lists of articles identified by the search
strategies.
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Selection criteria
All randomised controlled trials (RCTs) and quasi-randomised controlled trials looking at pharmacological interventions for Kleine-
Levin syndrome were eligible. We had planned to include both parallel-group and cross-over studies.
Data collection and analysis
Two review authors (MMO and CC) had planned to extract the data reported in the original articles.
Main results
No studies met the inclusion criteria for this systematic review.
Authors’ conclusions
Therapeutic trials of pharmacological treatment for Kleine-Levin syndrome with a double-blind, placebo-controlled design are needed.
P L A I N L A N G U A G E S U M M A R Y
Pharmacological treatment for Kleine-Levin syndrome
Background
Kleine-Levin syndrome (KLS) is a rare disorder that mainly affects adolescent men. It is characterised by recurrent episodes of hypersom-
nia (excessive sleepiness), hyperphagia (overeating), and abnormal behaviour. The frequency and nature of the attacks can disrupt the
individual’s social, professional, and family life. The cause of KLS is not known. Several treatments have been used, including stimulant,
anti-epileptic, anti-depressant, and anti-psychotic drugs, with some benefit reported, but because of the rarity of the condition, long-
term follow-up of participants is difficult.
Objectives
The authors of this review aimed to identify and evaluate randomised controlled trials (RCTs) studying the effectiveness of pharmaco-
logical treatment for Kleine-Levin syndrome.
Results
We were not able to find any RCTs. Good-quality evidence is therefore lacking, and therapeutic trials with a double-blind, placebo-
controlled design are needed.
The evidence was current to 7 April 2016.
B A C K G R O U N D
This review is an update of a previously published review in
the Cochrane Database of Systematic Reviews (2009. Issue 2) on
’Pharmacological treatment for Kleine-Levin syndrome’ (Oliveira
2013).
Kleine-Levin syndrome (KLS) is a rare disorder with an estimated
prevalence of one to five cases per million population (ISCD-3
2014) that mainly affects adolescent men. It is characterised by
recurrent episodes of hypersomnia, usually accompanied by hy-
perphagia, cognitive andmood disturbances, abnormal behaviour,
such as hypersexuality, and signs of dysautonomia (ICSD 1990;
Kleine 1925; Levin 1936; ISCD-3 2014).
In 1815, Satterley presented the case of a 16-year oldmale with hy-
persomnia and hyperphagia following a short period of fever and
headache. Kleine-Levin syndrome was first described by Kleine in
1925 (Kleine 1925); this description was elaborated on by Levin
in 1936 (Levin 1936), but it was not named Kleine-Levin syn-
drome until 1942, by Crichtley and Hoffman (Critchley 1942).
Kleine-Levin syndrome was further defined by Critchley in 1962
2Pharmacological treatment for Kleine-Levin syndrome (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Critchley 1962), and by Schmidt in 1990, who established the
following diagnostic criteria:
• Predominance in adolescent males;
• Onset in adolescence;
• Periodic hypersomnia;
• Hyper/mega/polyphagia;
• Association with behavioural and psychological changes;
• Benign clinical course with spontaneous disappearance of
clinical symptoms;
• Lack of other neurological or psychiatric disease.
In 1990, the diagnostic criteria for KLS were modified in the In-
ternational Classification of Sleep Disorders, where it was defined
as a syndrome comprised of recurring episodes of undue sleepi-
ness lasting some days, which may, or may not, be associated with
hyperphagia and abnormal behaviour (ICSD 1990). According to
the International Classification of Sleepiness Disorders, 3rd ver-
sion (ICSD-3), revised in 2014, Kleine-Levin syndrome is a rare
sleep disorder characterized by recurrent episodes of severe hy-
persomnia associated with cognitive and behavioral disturbances
such as confusion, derealization, apathy, compulsive eating, and
hypersexuality. Episodes last a few days to several weeks and are
separated by weeks or months of normal sleep and behavior. KLS
is categorized as a central disorder of hypersomnolence (ISCD-3
2014).
The cause of KLS remains unknown, although numerous atypical
or incomplete causes have been hypothesised:
• Diencephalic-hypothalamic dysfunction, reported with
hypothalamic and third ventricle tumours, has similar
symptoms, suggesting hypothalamic or circadian dysfunction as
a cause (Fulton 1929; Haugh 1983).
• Abnormalities in serotonin and dopamine metabolism have
been reported, suggesting a neurotransmitter imbalance in the
serotonergic or dopaminergic pathway (Chesson 1991; Koerber
1984).
• Inflammatory lesions in the thalamus, diencephalon and
midbrain have been described in postmortem neuropathological
case reports, suggesting a viral infection (Fenzi 1993; Merriam
1986; Salter 1993).
• Stress status, sleep deprivation, and alcohol abuse have also
been suggested as triggers of KLS (Russel 1992).
• A genetic basis for the disorder has been suggested by the
preponderance of cases in the Ashkenazi Jewish population,
suggesting a founder effect, as well as numerous reports of
familial cases. To date, however, no specific genes have been
identified (ISCD-3 2014).
Because of the frequency and the nature of the attacks a person
can suffer with KLS, individuals often experience disruption to
their social, family, and professional life.
Several treatment strategies have been used:
• Stimulant drugs (methylphenidate, modafinil, pemoline-
piracetam-meclofenoxate, D-amphetamine, ephedrine, meta-
amphetamine, amphetamine, etc.);
• Anti-epileptic drugs (valproic acid, carbamazepine,
amobarbital, phenobarbital, phenytoin, etc.);
• Anti-depressants (imipramine, monoamine oxidase
inhibitors (MAOIs), moclobemide, clomipramine, amineptine,
fluoxetine, fluvoxamine, sertraline, methysergide, trazodone,
etc.);
• Anti-psychotic drugs (haloperidol, chlorpromazine,
levomepromazine, trifluoperazine, thioridazine, clozapine,
risperidone, etc.);
• Anti-virals (acyclovir);
• Lithium;
• Hydrocortisone;
• Melatonin;
• Benzodiazepines;
• Levodopa-benserazide.
These medications have been reported to provide some benefit
in the treatment of patients with KLS, but because of the rarity
of the condition, no long-term follow-up therapies have yet been
described.
O B J E C T I V E S
This review aimed to evaluate:
(1) whether pharmacological treatment for Kleine-Levin syn-
drome was effective and safe;
(2) which drug or category of drugs was effective and safe.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
All randomised controlled trials (RCTs) of pharmacological treat-
ment for Kleine-Levin syndrome. We also had planned to include
quasi-randomised controlled trials (using inadequate allocation
assignment such as date of birth, day of the week or month of
the year, medical record number or alternate allocation). We had
planned to include both parallel-group and cross-over studies.
Types of participants
Inclusion criteria
We considered children and adults whomet the established clinical
criteria for KLS (Critchley 1962; ICSD 1990):
ICSD 1990:
• Recurring episodes of undue sleepiness lasting some days;
• Hyperphagia (not obligatory);
• Abnormal behaviour (not obligatory).
Critchley 1962:
• Predominance in adolescent males;
• Onset in adolescence;
• Periodic hypersomnia;
• Hyper/mega/polyphagia;
• Associated behavioural and psychological changes;
• Benign clinical course with spontaneous disappearance of
clinical symptoms;
• Lack of other neurological or psychiatric disease.
Exclusion criteria
We excluded studies that predominantly recruited participants
with narcolepsy, obstructive sleep apnoea, schizophrenia, bipo-
lar affective disorder, obsessive-compulsive disorder, frontal brain
tumour, third ventricle tumour, drug or alcohol abuse, en-
cephalopathies, bulimia, atypical depressive disease, and delayed
sleep maturation.
Types of interventions
We included all drugs used for the treatment of KLS.
Pharmacological interventions
• Stimulant drugs (methylphenidate, modafinil, pemoline-
piracetam-meclofenoxate, D-amphetamine, ephedrine, meta-
amphetamine, amphetamine, etc.);
• Anti-epileptic drugs (valproic acid, carbamazepine,
amobarbital, phenobarbital, phenytoin, etc.);
• Anti-depressants (imipramine, MAOIs, moclobemide,
clomipramine, amineptine, fluoxetine, fluvoxamine, sertraline,
methylsergide, trazodone, etc.);
• Anti-psychotic drugs (haloperidol, chlorpromazine,
levomepromazine, trifluoperazine, thioridazine, clozapine,
risperidone, etc.);
• Anti-viral (acyclovir);
• Lithium;
• Hydrocortisone;
• Melatonin;
• Benzodiazepines;
• Levodopa-benserazide.
Comparison groups
• Placebo;
• No intervention;
• Other drug treatments.
Types of outcome measures
Primary outcomes
• Relief of KLS symptoms (hypersomnia, hyperphagia,
abnormal behaviour) as measured by any objective or subjective
validated scale.
Secondary outcomes
• Subjective sleep quality (any description of sleep quality;
Epworth scale).
• Sleep quality, as measured by night polysomnography
(measured by sleep efficiency, total sleep time, arousal index).
• Quality of life, as measured by a validated scale such as
Short-Form Health Survey (SF-36), or a visual analogue scale.
• Adverse events associated with treatments (to be described
in terms of (i) numbers of participants withdrawing because of
adverse events; and (ii) numbers of participants describing any
side effect associated with the interventions).
Search methods for identification of studies
The search strategies used for the original version of this review
are recorded in Appendix 1. For the most recent update of this
review, we searched the following databases:
• The Cochrane Epilepsy Group Specialized Register (7 April
2016), using the search strategy set out in Appendix 2;
• The Cochrane Central Register of Controlled Trials
(CENTRAL) via the Cochrane Register of Studies Online CRSO
(7 April 2016), using the search strategy set out in Appendix 3;
• MEDLINE (Ovid, 1946 to 7 April 2016), using the search
strategy outlined in Appendix 4;
• LILACS (The Latin American and Caribbean Literature on
Health Sciences Database; 7 April 2016), using the search
strategy outlined in Appendix 5;
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• ClinicalTrials.gov (7 April 2016), using the search term:
“Kleine-Levin” OR “Kleine Levin”;
• WHO International Clinical Trials Registry Platform
ICTRP (7 April 2016), using the search term: Kleine-Levin OR
Kleine Levin in the Condition.
Previously, we searched SCOPUS as an alternative to EMBASE,
using the search strategy outlined in Appendix 6, but this is no
longer necessary, because randomised and quasi-randomised con-
trolled trials in EMBASE are now included in CENTRAL.
We also searched the reference lists of sleep medicine textbooks,
review articles, and the reference lists of articles identified by the
search strategies described here.
Data collection and analysis
Selection of studies
Two review authors (MMO and CC) undertook the review. We
used the broad search strategy already described to obtain the
titles and abstracts of studies pertaining to KLS of any cause. The
same two review authors independently screened the titles and
abstracts, and discarded studies that were not applicable; however,
they initially retained studies and reviews that might have included
relevant data or informationon trials. The same two review authors
independently assessed the retrieved abstracts, and if necessary, the
full text of these studies to determine which studies satisfied the
inclusion criteria.
We found no studies that met the eligibility criteria for inclusion.
If studies that meet the inclusion criteria are identified for future
updates of this review, we will apply the following methodology.
Data extraction and management
The same two review authors will independently carry out data ex-
traction using standard data extraction forms, and then indepen-
dently enter the data into the Review Manager software (RevMan
2012). We will translate studies reported in non-English language
journals before assessment. When more than one publication of a
trial exists, we will group the articles, and for each available out-
come, we will extract results from the publication with the most
complete data. We will request any further information required
from the original author by written correspondence, and will in-
clude any relevant information obtained in this manner in the re-
view. We will resolve disagreements in consultation with a third
review when necessary.
Assessment of risk of bias in included studies
The two review authors will independently assess the risk of bias
of the studies to be included, without blinding to authorship or
journal, using the new Cochrane ’Risk of bias’ tool (Higgins
2011).We will resolve discrepancies by discussion with GFP. ’Risk
of bias’ factors to be assessed include: randomisation, allocation
concealment, blinding of investigators, participants and outcomes
assessors, completeness of follow-up, selective reporting,
Measures of treatment effect
Dichotomous outcomes
For dichotomous outcomes (such as frequency of adverse reactions
requiring withdrawal), we will express results as relative risk (RR)
with 95% confidence interval (CI). We will pool data using the
random-effects model but will also analyse the fixed-effect model
to ensure the robustness of the model chosen and susceptibility to
outliers.
Continuous outcomes
When continuous scales of measurement are used to assess the
effects of treatment (such as various of KLS symptoms or effects
on quality of life), we will use the mean difference (MD), or the
standardised mean difference (SMD) if different scales have been
used.
Dealing with missing data
If possible, we will perform all analyses according to the intention-
to-treat method, using the last reported observed response (’carry
forward’) and including all participants regardless of compliance
or follow-up.
Assessment of heterogeneity
We will analyse heterogeneity using the Q statistic, a Chi² test on
N-1 degrees of freedom, with an alpha of 0.10 used for statistical
significance. We will also quantify inconsistency with the I² statis-
tic, calculated by [(Q df)/Q × 100%], which describes the per-
centage of variability in effect estimates caused by heterogeneity
rather than by sampling error. A value greater than 50% will be
considered to signify substantial heterogeneity (Higgins 2011).
When sufficient data are available, we will pool study findings ac-
cording to subcategory to explore possible sources of heterogene-
ity. We will divide the studies according to the following:
• Age of participants;
• Severity of the disorder;
• Type of medication given;
• Methodological quality of the study (allocation
concealment, blinding, intention-to-treat analysis).
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Sensitivity analysis
We will perform ’a worst case scenario’ analysis and will consider
participants with missing data as treatment failures.
R E S U L T S
Description of studies
We initially identified 257 studies using the search strategy.
(1) Excluded studies
The search identified 36 potentially eligible studies from the
sources previously described. Of these, none were ultimately in-
cluded in the review. All 36 studies were excluded because of
study design: all were case reports or reviews. See the table of
’Characteristics of excluded studies’ for details.
(2) Ongoing studies
The review authors know of no ongoing studies.
(3) Included studies
No studies met the eligibility criteria for inclusion.
Risk of bias in included studies
No studies met the eligibility criteria for inclusion.
Effects of interventions
No studies met the eligibility criteria for inclusion.
D I S C U S S I O N
We found no randomised, placebo-controlled trials of pharmaco-
logical treatments for KLS, and no studies could be included in
this review. Kleine-Levin syndrome has a benign clinical course
with spontaneous disappearance of symptoms; the findings of case
reports excluded from this review were unpredictable. However,
some case reports have described improvement in specific symp-
toms of KLS as follows:
• Stimulant drugs, especially amphetamines, significantly
improved sleepiness but did not improve other symptoms
(Gallinek 1962).
• Anti-depressant drugs had no effect on preventing relapse,
except in one case, in which a monoamine oxidase inhibitor
(moclobemide) was used (Chaudhry 1992).
• Anti-epileptic drugs showed, in a single case, improvement
in abnormal behaviour when carbamazepine was used
(Mukaddes 1999).
• Lithium significantly improved abnormal behaviour and
recovery of symptoms (reducing the duration of episodes and
decreasing relapses) (Kellet 1977; Poppe 2003; Smolik 1988).
Unfortunately, no evidence was available to support the use of
these therapies.
It is important to remember that the frequent occurrence of attacks
andof severe behavioural disorders incapacitates patientswithKLS
both professionally and socially. We believe that double-blind,
placebo-controlled therapeutical trials of drugs that can prevent or
improve all symptoms of KLS are warranted, and that because of
the rarity of the condition, these trials should have a multicentre
design.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
No evidence indicated that pharmacological treatment for Kleine-
Levin syndrome was effective and safe.
Implications for research
Therapeutic, double-blind, placebo-controlled drug trials for
Kleine-Levin syndrome are needed that use a robust methodol-
ogy, and in the light of the rarity of this condition, a multicentre
design.
A C K N OW L E D G E M E N T S
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Search strategies for original version of this review
We searched the Cochrane Epilepsy Group Specialized Register (1 December 2007) and the Cochrane Central Register of Controlled
Trials (CENTRAL) (The Cochrane Library Issue 3, 2007) using the following terms
:#1 KLEINE-LEVIN SYNDROME
#2 (Kleine-Levin* next syndrome*)
#3 (periodic next hypersomnia next sleep*)
#4 (compulsive next eating*)
#5 (hyperphagia or megaphagia or polyphagia*)
#6 (hypersexuality)
#7 (KLS)
#8 (#1 or #2 or #3 or #4 or #5 or #6 or #7)
We also searched the following electronic databases.
- MEDLINE (1966 to December 2007) using the optimally sensitive strategy developed for the Cochrane Collaboration for the
identification of randomized controlled trials (Dickersin 1994).
- EMBASE (1980 to December 2007) using a search strategy adapted from that developed for the Cochrane Collaboration for the
identification of randomized controlled clinical trials (Lefebvre 1996).
- LILACS (1982 to December 2007) using a search strategy adapted for the identification of randomized controlled clinical trials.
MEDLINE search strategy (1966 to December 2007)
((kleine[All Fields] AND levin[All Fields]) OR (“kleine-levin syndrome”[MeSH Terms] OR kleine levin syndrome[Text Word])) AND
(megaphagia[All Fields] OR ((“disorders of excessive somnolence”[TIAB] NOT Medline[SB]) OR “disorders of excessive somno-
lence”[MeSH Terms] OR hypersomnia[Text Word]) OR hypersexuality[All Fields] OR (“hyperphagia”[MeSH Terms] OR hyperpha-
gia[Text Word]))
EMBASE search strategy (1980 to December 2007)
’kleine levin’ AND (’syndrome’/expOR ’syndrome’) AND ’kleine levin’ AND (’hyperphagia’/expOR ’hyperphagia’) ANDmegaphagia
AND (’polyphagia’/exp OR ’polyphagia’) AND (’hypersomnia’/exp OR ’hypersomnia’) AND periodic AND (’hypersomnia’/exp OR
’hypersomnia’) AND (’hypersexuality’/exp OR ’hypersexuality’) AND kls
LILACS search strategy (1982 to December 2007)
“sindrome de KLEINE-levin” or (tw kleine and tw levin) [Descritor de assunto]
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Appendix 2. Cochrane Epilepsy Group Specialized Register search strategy
#1 MeSH DESCRIPTOR Kleine-Levin Syndrome Explode All
#2 Kleine-Levin* next syndrome*
#3 periodic next hypersomnia next sleep*
#4 compulsive next eating*
#5 hyperphagia or megaphagia or polyphagia*
#6 hypersexuality
#7 KLS
#8 (#1 or #2 or #3 or #4 or #5 or #6 or #7) AND INREGISTER AND >02/05/2013:CRSCREATED
Appendix 3. CENTRAL via CRSO search strategy
#1 MESH DESCRIPTOR Kleine-Levin Syndrome EXPLODE ALL TREES
#2 (Kleine AND Levin):TI,AB,KY
#3 #1 OR #2
#4 31/05/2013 TO 31/07/2015:DL
#5 #3 AND #4
Appendix 4. MEDLINE search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials published in Lefebvre 2011.
1. exp Kleine-Levin Syndrome/
2. (Kleine and Levin).tw.
3. 1 or 2
4. (randomized controlled trial or controlled clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
5. clinical trials as topic.sh.
6. trial.ti.
7. 4 or 5 or 6
8. exp animals/ not humans.sh.
9. 7 not 8
10. 3 and 9
11. limit 10 to ed=20130502-20150707
Appendix 5. LILACS search strategy
(tw:(“kleine levin”)) OR (mh:(“kleine-levin syndrome”)) AND (instance:“regional”) AND ( type˙of˙study:(“case˙control” OR “co-
hort”))
Appendix 6. SCOPUS search strategy
(TITLE(“Kleine-Levin”) OR ABS(“Kleine-Levin”)) AND (TITLE((randomiz* OR randomis* OR controlled OR placebo OR blind*
OR unblind* OR “parallel group” OR crossover OR “cross over” OR cluster OR “head to head”) PRE/2 (trial OR method OR
procedure OR study)) OR ABS((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR “parallel group”
OR crossover OR “cross over” OR cluster OR “head to head”) PRE/2 (trial OR method OR procedure OR study)))
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WH A T ’ S N E W
Last assessed as up-to-date: 7 April 2016.
Date Event Description
7 April 2016 New search has been performed Searches updated 7 April 2016.
7 April 2016 New citation required but conclusions have not changed No new studies identified; conclusions are unchanged.
H I S T O R Y
Protocol first published: Issue 3, 2007
Review first published: Issue 2, 2009
Date Event Description
7 May 2013 New citation required but conclusions have not changed Conclusions unchanged.
2 May 2013 New search has been performed Searches updated; no new studies identified.
13 March 2012 New search has been performed Searches updated 24October 2011; nonew studies iden-
tified.
5 March 2010 New search has been performed Searches updated 5March 2010; nonew trials identified.
19 August 2008 Amended Converted to new review format.
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